Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

P. Marso, Steven; C. Bain, Stephen; Consoli, Agostino; G. Eliaschewitz, Freddy; Jódar, Esteban; A. Leiter, Lawrence; Lingvay, Ildiko; Rosenstock, Julio; Seufert, Jochen; Warren, Mark; Woo, Vincent; H. Hansen, Oluf; G. Holst, Anders; Pettersson, Jonas; Vilsbøll, Tina

doi:10.1056/nejmoa1607141

Public

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Published in New England Journal of Medicine • Sep 16, 2016

Authors:

Steven P. Marso

Stephen C. Bain

Agostino Consoli

Abstract

BACKGROUND: Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. METHODS: We assessed cardiovascular outcomes of once-...

Subject

Semaglutide

Type 2 diabetes

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!